EXAS vs. PRAH, MEDP, CRL, SYNH, BIIB, ALNY, BMRN, INCY, UTHR, and NBIX
Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include PRA Health Sciences (PRAH), Medpace (MEDP), Charles River Laboratories International (CRL), Syneos Health (SYNH), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.
Exact Sciences (NASDAQ:EXAS) and PRA Health Sciences (NASDAQ:PRAH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, Exact Sciences had 18 more articles in the media than PRA Health Sciences. MarketBeat recorded 18 mentions for Exact Sciences and 0 mentions for PRA Health Sciences. Exact Sciences' average media sentiment score of 0.31 beat PRA Health Sciences' score of 0.00 indicating that Exact Sciences is being referred to more favorably in the media.
88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 93.9% of PRA Health Sciences shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by company insiders. Comparatively, 1.3% of PRA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
PRA Health Sciences has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Exact Sciences has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, PRA Health Sciences has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Exact Sciences presently has a consensus price target of $85.80, indicating a potential upside of 89.40%. Given Exact Sciences' higher probable upside, equities analysts clearly believe Exact Sciences is more favorable than PRA Health Sciences.
Exact Sciences received 588 more outperform votes than PRA Health Sciences when rated by MarketBeat users. Likewise, 72.57% of users gave Exact Sciences an outperform vote while only 55.86% of users gave PRA Health Sciences an outperform vote.
PRA Health Sciences has a net margin of 6.40% compared to Exact Sciences' net margin of -9.48%. PRA Health Sciences' return on equity of 20.49% beat Exact Sciences' return on equity.
Summary
PRA Health Sciences beats Exact Sciences on 10 of the 17 factors compared between the two stocks.
Get Exact Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exact Sciences Competitors List
Related Companies and Tools
